Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, David T. Rubin et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority TrialWolfgang Kruis, Roland Greinwald, Britta Siegmund et al.|Journal of Crohn s and Colitis|2022Cited by 15
Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome Is Another Key to the Pathogenesis of Inflammatory Bowel DiseaseС. И. Ситкин, Juris Pokrotnieks, Elena Demyanova et al.|Inflammatory Bowel Diseases|2019Cited by 6